Correlations Between Bone Mineral Density Changes in Postmenopausal Women Using Dual Energy X-ray Absorptiometry

2018 ◽  
Vol 41 (1) ◽  
pp. 47-51
Author(s):  
Seung Hun Jeong ◽  
Tae Hui Lee ◽  
Dong Woo Kim
2005 ◽  
Vol 24 (7) ◽  
pp. 941-946 ◽  
Author(s):  
Bagher Larijani ◽  
Mohammad Hossein Dabbaghmanesh ◽  
Shahriar Aghakhani ◽  
Mojtaba Sedaghat ◽  
Zohreh Hamidi ◽  
...  

2017 ◽  
Vol 7 (1) ◽  
pp. 59-67
Author(s):  
Amila Jaganjac ◽  
Mirsad Muftić ◽  
Dijana Avdić ◽  
Amra Mačak Hadžiomerović ◽  
Bakir Katana ◽  
...  

Introduction: Osteoporosis is a skeletal system disease characterized by decline of bone mass and deterioration of bone microarchitecture, which leads to increased bone fragility and, consequently, a greater risk of fractures. Postmenopausal osteoporosis generally occurs between 51 and 75 years of age following ovarian failure. Our aim was to investigate if specific lifestyle habits, i.e., smoking cigarettes and physical activity, as well as the intake of dietary supplements, affect bone mineral density (BMD) in postmenopausal women.Methods: Ultrasound (US) and dual energy X-ray absorptiometry (DEXA) data, obtained between 2008 and 2009 year, were retrospectively reviewed for 150 women in postmenopause, 50-65 years old, who live in Sarajevo Canton. The women were classified into two groups: Group A (75 postmenopausal women who underwent US of the left heel bone); control group B (75 postmenopausal women who underwent US of the left heel bone and had a DEXA scan of the lumbar spine and left hip).Results: The study included 150 women with the average age of 55.39 years. In the total sample, 24.7% of women took calcium and vitamin D supplements, and no statistically significant difference was observed between the groups. In the total sample, the prevalence of osteoporosis was significantly different between smokers and nonsmokers; i.e., osteoporosis was more frequent in women who smoked cigarettes. On average, women in both groups reported low physical activity; the difference was not statistically significant.Conclusions: Menopause is a known risk for osteoporosis. Our results showed that the length of menopause is closely associated with osteoporosis occurrence.


1996 ◽  
Vol 14 (1) ◽  
pp. 78-84 ◽  
Author(s):  
T J Powles ◽  
T Hickish ◽  
J A Kanis ◽  
A Tidy ◽  
S Ashley

PURPOSE Tamoxifen is an effective treatment for metastatic and primary breast cancer and is now being evaluated as a chemoprevention agent in healthy women. Any long-term effects on estrogen-sensitive tissues such as bone may have important therapeutic implications. METHODS We measured bone mineral density (BMD) in the lumbar spine and hip using dual-energy x-ray absorptiometry (DXA) in premenopausal and postmenopausal healthy women who participated in our placebo-controlled tamoxifen chemoprevention of breast cancer trial. RESULTS BMD data are now available from 179 women for this analysis. In premenopausal women, BMD decreased progressively in the lumbar spine (P < .001) and in the hip (P < .05) for women on tamoxifen, but not those on placebo. The mean annual loss in lumbar BMD per year over the 3-year study period in tamoxifen-treated compliant women who remained premenopausal throughout the study period was 1.44% (1.88% calculated on an intent-to-treat basis) compared with a small gain of 0.24% per annum for women on placebo (P < .001). Tamoxifen had the opposite effect in postmenopausal women. The mean annual increase in BMD for women on tamoxifen was 1.17% in the spine (P < .005) and 1.71% in the hip (P < .001) compared with a noninsignificant loss for women on placebo. CONCLUSION These results indicate that tamoxifen treatment is associated with a significant loss of BMD in premenopausal women, whereas it prevents bone loss in postmenopausal women. These adverse and beneficial effects of tamoxifen should be considered in the assessment of the therapeutic benefits for both the adjuvant treatment and the chemoprevention of breast cancer.


2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 227.2-228
Author(s):  
D. Claire ◽  
M. Geoffroy ◽  
L. Kanagaratnam ◽  
C. Isabelle ◽  
A. Hittinger ◽  
...  

Background:Dual energy X-ray absoprtiometry is the reference method to mesure bone mineral density (1). Loss of bone mineral density is significant if it exceeds the least significant change. The threshold value used in general population is 0,03 g/cm2 (2). Patients with obesity are known for having a higher bone mineral density due to metabolism and physiopathology characteristics (3,4).Objectives:The aim of our study was to determine the least significant change in bone densitometry in patients with obesity.Methods:We conducted an interventionnal study in 120 patients with obesity who performed a bone densitometry. We measured twice the bone mineral density at the lumbar spine, the femoral neck and the total hip in the same time (5,6). We determined the least significant change in bone densitometry from each pair of measurements, using the Bland and Altman method. We also determined the least significant change in bone densitometry according to each stage of obesity.Results:The least significant change in bone densitometry in patients with obesity is 0,046g/cm2 at the lumbar spine, 0.069 g/cm2 at the femoral neck and 0.06 g/cm2 at the total hip.Conclusion:The least significant change in bone densitometry in patients with obesity is higher than in general population. These results may improve DXA interpretation in this specific population, and may personnalize their medical care.References:[1]Lees B, Stevenson JC. An evaluation of dual-energy X-ray absorptiometry and comparison with dual-photon absorptiometry. Osteoporos Int. mai 1992;2(3):146-52.[2]Briot K, Roux C, Thomas T, Blain H, Buchon D, Chapurlat R, et al. Actualisation 2018 des recommandations françaises du traitement de l’ostéoporose post-ménopausique. Rev Rhum. oct 2018;85(5):428-40.[3]Shapses SA, Pop LC, Wang Y. Obesity is a concern for bone health with aging. Nutr Res N Y N. mars 2017;39:1-13.[4]Savvidis C, Tournis S, Dede AD. Obesity and bone metabolism. Hormones. juin 2018;17(2):205-17.[5]Roux C, Garnero P, Thomas T, Sabatier J-P, Orcel P, Audran M, et al. Recommendations for monitoring antiresorptive therapies in postmenopausal osteoporosis. Jt Bone Spine Rev Rhum. janv 2005;72(1):26-31.[6]Ravaud P, Reny JL, Giraudeau B, Porcher R, Dougados M, Roux C. Individual smallest detectable difference in bone mineral density measurements. J Bone Miner Res. août 1999;14(8):1449-56.Disclosure of Interests:None declared.


Sign in / Sign up

Export Citation Format

Share Document